• Akeso reported its Phase III HARMONi-GI1 study hit the primary overall survival endpoint in first-line advanced biliary tract cancer.
• Ivonescimab with chemotherapy outperformed durvalumab with chemotherapy, showing a statistically significant, clinically meaningful survival benefit.
• The trial also achieved key secondary endpoints, supporting a broader push for ivonescimab beyond lung cancer into gastrointestinal tumors.
• Results have not yet been disclosed in full, with detailed findings slated for a future international medical conference presentation.
• The study enrolled 682 patients, positioning the readout as a potential catalyst for regulatory and commercial planning in biliary tract cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299372), on August 25, 2026, and is solely responsible for the information contained therein.